Phase I study of vorinostat as a radiation sensitizer with 131I-metaiodobenzylguanidine (131I-MIBG) for patients with relapsed or refractory neuroblastoma

Clinical Cancer Research

Volumn 21, Issue 12, 2015, Pages 2715-2721

  DuBois, Steven G ^a   Groshen, Susan ^b   Park, Julie R ^c   Haas Kogan, Daphne A ^a   Yang, Xiaodong ^a   Geier, Ethan ^d   Chen, Eugene ^d   Giacomini, Kathy ^d   Weiss, Brian ^e   Cohn, Susan L ^f   Granger, M Meaghan ^g   Yanik, Gregory A ^h   Hawkins, Randall ^a   Courtier, Jesse ^a   Jackson, Hollie ^b   Goodarzian, Fariba ^b   Shimada, Hiroyuki ^b   Czarnecki, Scarlett ^b   Tsao Wei, Denice ^b   Villablanca, Judith G ^b   Marachelian, Araz ^b   Matthay, Katherine K ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g Pediatric Cardiothoracic Surgery   (United States)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; VORINOSTAT; (3 IODOBENZYL)GUANIDINE; HISTONE; HYDROXAMIC ACID; NORADRENALIN TRANSPORTER; RADIOACTIVE IODINE; RADIOSENSITIZING AGENT; SLC6A2 PROTEIN, HUMAN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN HEMORRHAGE; CANCER RECURRENCE; CHEMORADIOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENE EXPRESSION; HEADACHE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HYPERAMYLASEMIA; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOKALEMIA; INDUCTION CHEMOTHERAPY; INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; NAUSEA; NEUROBLASTOMA; NEUTROPENIA; ORAL BLEEDING; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; RADIATION DOSE; RADIOSENSITIZATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING; WHOLE BODY RADIATION; ACETYLATION; CLINICAL TRIAL; DRUG MONITORING; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME; TUMOR RECURRENCE; YOUNG ADULT;

3-IODOBENZYLGUANIDINE; ACETYLATION; ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; HISTONES; HUMANS; HYDROXAMIC ACIDS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; RADIATION-SENSITIZING AGENTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84941979029     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3240     Document Type: Article

References (26)

1. Du Bois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999;21:181-9.
2. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20.
3. Castleberry RP, Kun LE, Shuster JJ, Altshuler G, Smith IE, Nitschke R, et al. Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. J Clin Oncol 1991;9: 789-95.
4. Du Bois SG, Matthay KK. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol 2008;35:S35-48.
5. Du Bois SG, Geier E, Batra V, Yee SW, Neuhaus J, Segal M, et al. Evaluation of norepinephrine transporter expression and metaiodobenzylguanidine avidity in neuroblastoma: a report from the children's oncology group. Int J Mol Imaging 2012;2012:250834.
6. Treuner J, Feine U, Niethammer D, Muller-Schaumburg W, Meinke J, Eibach E, et al. Scintigraphic imaging of neuroblastoma with [131-I]iodobenzylguanidine. Lancet 1984;1:333-4.
7. Matthay KK, De Santes K, Hasegawa B, Huberty J, Hattner RS, Ablin A, et al. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998; 16:229-236.
8. Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007;25:1054-60.
9. Wilson JS, Gains JE, Moroz V, Wheatley K, Gaze MN. A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer 2014;50:801-15.
10. Dubois SG, Messina J, Maris JM, Huberty J, Glidden DV, Veatch J, et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 2004;22: 2452-60.
11. Du Bois SG, Chesler L, Groshen S, Hawkins R, Goodarzian F, Shimada H, et al. Phase I study of vincristine, irinotecan, and (1)(3)(1)I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clin Cancer Res 2012;18:2679-86.
12. Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005;20:195-9.
13. Mastrangelo R, Tornesello A, Lasorella A, Iavarone A, Mastrangelo S, Riccardi R, et al. Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma. J Neurooncol 1997; 31:153-8.
14. Mueller S, Yang X, Sottero TL, Gragg A, Prasad G, Polley MY, et al. Cooperation of the HDAC inhibitor vorinostat and radiation inmetastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett 2011; 306:223-9.
15. More SS, Itsara M, Yang X, Geier EG, Tadano MK, Seo Y, et al. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clin Cancer Res 2011;17: 2339-49.
16. Keshelava N, Houghton PJ, Morton CL, Lock RB, Carol H, Keir ST, et al. Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer 2009;53:505-8.
17. Sun Y, Liu PY, Scarlett CJ, Malyukova A, Liu B, Marshall GM, et al. Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc. Oncogene 2014;33:2987-94.
18. Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol 2010;28:3623-9.
19. Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, et al. Vorinostat, a histone deacetylase inhibitor, combinedwith pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol 2010;11:459-64.
20. Shi W, Lawrence YR, Choy H, Werner-Wasik M, Andrews DW, Evans JJ, et al. Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial. J Neurooncol 2014;118:313-9.
21. Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 2001;42:1713-21.
22. Camphausen K, Tofilon PJ. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol 2007;25:4051-6.
23. Hummel TR, Wagner L, Ahern C, Fouladi M, Reid JM, McGovern RM, et al. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer 2013;60:1452-7.
24. Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, et al. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 2009;101: 1044-50.
25. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23:3923-31.
26. Traynor AM, Dubey S, Eickhoff JC, Kolesar JM, Schell K, Huie MS, et al. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J Thorac Oncol 2009;4:522-6.